BACKGROUND Company: Top 50 pharmaceutical company Indication: Polycystic kidney disease Phase: III CHALLENGE To better understand and define disease progression and treatment response, the sponsor was challenged to generate study efficacy data beyond glomerular flow rate (GFR) and basic kidney volume. To achieve this, ERT was engaged to adapt its image processing and analysis software to automatically generate static (single time point) and longitudinal (multiple time points) kidney- and cyst-level, quantitative data using magnetic resonance imaging (MRI). Segmented cysts (green) Cyst (gray) Imaging technology that delivers results without the typical human bias. To learn more, go to ert.com info@ert.com. RESULTS The use of ERT’s imaging software enabled objective, reproducible and q

Join for free to read